LZTS2 antibody is predicted to not cross-react with other LZTS family members
Purification
LZTS2 Antibody is affinity chromatography purified via peptide column.
Immunogen
LZTS2 antibody was raised against a 19 amino acid synthetic peptide near the amino terminus of human LZTS2. The immunogen is located within amino acids 80 - 130 of LZTS2.
LZTS2
Reactivity: Human
WB
Host: Mouse
Polyclonal
unconjugated
Application Notes
LZTS2 antibody can be used for detection of EPAC1 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
LZTS2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
LZTS2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
LZTS2 Antibody: The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.